ALK and non-small cell lung carcinoma: In this review, we provide an overview of the main relevant clinical trials in the setting of neoadjuvant–preoperative–adjuvant treatment using iCIs in early-stage NSCLC, excluding patients with mutations of EGFR/ALK.